[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 647, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 60, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 2568666, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "age": 48, "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher  Williams", "age": 44, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthias  Will M.D.", "age": 51, "title": "Senior VP & Chief Development Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 52, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 54, "title": "Senior VP, CFO & Principal Accounting Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 59, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 68, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "age": 59, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.5, "open": 1.5, "dayLow": 1.5, "dayHigh": 1.59, "regularMarketPreviousClose": 1.5, "regularMarketOpen": 1.5, "regularMarketDayLow": 1.5, "regularMarketDayHigh": 1.59, "payoutRatio": 0.0, "beta": 1.869, "forwardPE": -2.1369863, "volume": 3311604, "regularMarketVolume": 3311604, "averageVolume": 3262582, "averageVolume10days": 5325120, "averageDailyVolume10Day": 5325120, "bid": 1.52, "ask": 1.61, "bidSize": 8, "askSize": 8, "marketCap": 415180576, "fiftyTwoWeekLow": 1.105, "fiftyTwoWeekHigh": 5.0, "allTimeHigh": 53.24, "allTimeLow": 1.105, "priceToSalesTrailing12Months": 13.869866, "fiftyDayAverage": 1.8551, "twoHundredDayAverage": 1.9273, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 270067616, "profitMargins": 0.0, "floatShares": 118518093, "sharesOutstanding": 266141411, "sharesShort": 10606444, "sharesShortPriorMonth": 14901573, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.0399, "heldPercentInsiders": 0.18086, "heldPercentInstitutions": 0.84032, "shortRatio": 2.3, "shortPercentOfFloat": 0.0525, "impliedSharesOutstanding": 266141411, "bookValue": 1.302, "priceToBook": 1.1981566, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -227780992, "trailingEps": -0.87, "forwardEps": -0.73, "enterpriseToRevenue": 9.022, "enterpriseToEbitda": -1.034, "52WeekChange": -0.57024795, "SandP52WeekChange": 0.1529237, "quoteType": "EQUITY", "currentPrice": 1.56, "targetHighPrice": 13.0, "targetLowPrice": 5.0, "targetMeanPrice": 9.62222, "targetMedianPrice": 10.0, "recommendationMean": 1.1, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 454279008, "totalCashPerShare": 1.707, "ebitda": -261311008, "totalDebt": 309166016, "quickRatio": 7.819, "currentRatio": 8.426, "totalRevenue": 29934000, "debtToEquity": 89.235, "revenuePerShare": 0.115, "returnOnAssets": -0.21431999, "returnOnEquity": -0.52105, "grossProfits": -154510000, "freeCashflow": -237942880, "operatingCashflow": -263020000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -2.92582, "financialCurrency": "USD", "symbol": "AUTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "fiftyTwoWeekLowChange": 0.45499992, "fiftyTwoWeekLowChangePercent": 0.41176462, "fiftyTwoWeekRange": "1.105 - 5.0", "fiftyTwoWeekHighChange": -3.44, "fiftyTwoWeekHighChangePercent": -0.688, "fiftyTwoWeekChangePercent": -57.024796, "earningsTimestamp": 1754971200, "earningsTimestampStart": 1754971200, "earningsTimestampEnd": 1754971200, "earningsCallTimestampStart": 1755001800, "earningsCallTimestampEnd": 1755001800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.87, "epsForward": -0.73, "epsCurrentYear": -0.84252, "priceEpsCurrentYear": -1.851588, "fiftyDayAverageChange": -0.2951001, "fiftyDayAverageChangePercent": -0.15907504, "twoHundredDayAverageChange": -0.36730003, "twoHundredDayAverageChangePercent": -0.1905775, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1758929752, "regularMarketTime": 1758916801, "exchange": "NMS", "messageBoardId": "finmb_562879769", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 4.0, "regularMarketPrice": 1.56, "postMarketChangePercent": 2.56411, "postMarketPrice": 1.6, "postMarketChange": 0.0400001, "regularMarketChange": 0.0599999, "regularMarketDayRange": "1.5 - 1.59", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 3262582, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1529674200000, "displayName": "Autolus Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-27"}]